ALTERNATING WEEKLY TEMOZOLOMIDE AS INITIAL TREATMENT FOR PROGRESSIVE LOW-GRADE OLIGODENDROGLIAL TUMORS: A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY

被引：0
|
作者：
Soffietti, Riccardo [1 ]
Roda, Roberta [1 ]
Trevisan, Elisa [1 ]
Laguzzi, Elena [1 ]
Picco, Elisabetta [1 ]
Guarneri, Dainele [1 ]
Caroli, Manuela [2 ]
Crippa, Flavio [3 ]
机构：
[1] Univ Turin, Turin, Italy
[2] Univ Milan, Milan, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
NEURO-ONCOLOGY | 2008年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：838 / 838
页数：1
相关论文
共 50 条
  • [41] Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)
    Giuseppe Lombardi
    Andrea Pace
    Francesco Pasqualetti
    Simona Rizzato
    Marina Faedi
    Elena Anghileri
    Elisa Nicolotto
    Elena Bazzoli
    Luisa Bellu
    Veronica Villani
    Alessandra Fabi
    Patrizia Ferrazza
    Lorena Gurrieri
    Monia Dall’Agata
    Marica Eoli
    Alessandro Della Puppa
    Ardi Pambuku
    Domenico D’Avella
    Franco Berti
    Roberta Rudà
    Vittorina Zagonel
    Journal of Neuro-Oncology, 2015, 125 : 359 - 367
  • [42] Temozolomide (TMZ) for progressive primitive brain tumors:: safety at 75 mg/m2 a day for 21 days every 28:: A GICNO (Italian Neuro-Oncology Group) study.
    Brande, AA
    Cavallo, G
    Tosoni, A
    Ermani, M
    Franceschi, E
    Scopece, L
    Ghimenton, C
    Blatt, V
    Nicolardi, L
    Crinò, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 124S - 124S
  • [43] Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study
    Lassaletta, Alvaro
    Scheinemann, Katrin
    Zelcer, Shayna M.
    Hukin, Juliette
    Wilson, Beverley A.
    Jabado, Nada
    Carret, Anne Sophie
    Lafay-Cousin, Lucie
    Larouche, Valerie
    Hawkins, Cynthia E.
    Pond, Gregory Russell
    Poskitt, Ken
    Keene, Daniel
    Johnston, Donna L.
    Eisenstat, David D.
    Krishnatry, Rahul
    Mistry, Matthew
    Arnoldo, Anthony
    Ramaswamy, Vijay
    Huang, Annie
    Bartels, Ute
    Tabori, Uri
    Bouffet, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (29) : 3537 - +
  • [44] Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
    Claringbold, Phillip G.
    Price, Richard A.
    Turner, J. Harvey
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 561 - 569
  • [45] Temozolomide (TMZ) 3 weeks on/1 week off in the treatment of progressive low grade gliomas: A phase II GICNO study.
    Brandes, A. A.
    Tosoni, A.
    Cavallo, G.
    Scopece, L.
    Gardiman, M.
    Berti, F.
    Pasetto, L. M.
    Ferrarese, F.
    Blatt, V.
    Ermani, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 61S - 61S
  • [46] Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM)
    Carmen Balaña
    Antonio López-pousa
    Alfonso Berrocal
    Ricardo Yaya-tur
    Ana Herrero
    Jose-luis García
    Javier Martín-broto
    Manuel Benavides
    Miguel Cerdá-nicolás
    Rosa Ballester
    Josep Balart
    Jaume Capellades
    Journal of Neuro-Oncology, 2004, 70 : 359 - 370
  • [47] Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease.: A study of the Spanish Medical Neuro-Oncology Group (GENOM)
    Balaña, C
    López-Pousa, A
    Berrocal, A
    Yaya-Tur, R
    Herrero, A
    García, JL
    Martín-Broto, J
    Benavides, M
    Cerdá-Nicolás, M
    Ballester, R
    Balart, J
    Capellades, J
    JOURNAL OF NEURO-ONCOLOGY, 2004, 70 (03) : 359 - 369
  • [48] NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS
    Fisher, Barbara
    Zhang, Peixin
    Macdonald, David
    Chakravarti, Arnab
    Lesser, Glenn
    Fox, Sherry
    Coons, Stephen
    Rogers, Leland
    Werner-Wasik, Maria
    Doyle, Thomas
    Bahary, Jean-Paul
    Fiveash, John
    Bovi, Joseph
    Howard, Steven
    Yu, Michael
    Dsouza, David
    Laack, Nadia
    Roach, Mack
    Kwok, Young
    Wahl, Daniel
    Stasser, John
    Won, Minhee
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2018, 20 : 11 - 11
  • [49] BINIMETINIB IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA NOT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1: INITIAL RESULTS FROM A MULTI-INSTITUTIONAL PHASE II STUDY
    Robison, Nathan
    Pauly, Jasmine
    Malvar, Jemily
    Gardner, Sharon
    Allen, Jeffrey
    MacDonald, Tobey
    Aguilera, Dolly
    Baxter, Patricia
    Bendel, Anne
    Kilburn, Lindsay
    Leary, Sarah
    Bowers, Daniel
    Dorris, Kathleen
    Gauvain, Karen
    Alva, Elizabeth
    Cohen, Kenneth
    Nazemi, Kellie
    Tan, Yi Juin
    Margol, Ashley
    Dhall, Girish
    Rosser, Tena
    Davidson, Tom
    Plant, Ashley
    Ullrich, Nicole
    Bandopadhayay, Pratiti
    Agar, Nathalie
    Ligon, Keith
    Sposto, Richard
    Wright, Karen
    Kieran, Mark
    NEURO-ONCOLOGY, 2020, 22 : 376 - 376
  • [50] A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
    Fangusaro, Jason
    Onar-Thomas, Arzu
    Wu, Shengjie
    Poussaint, Tina Young
    Packer, Roger
    Kilburn, Lindsay
    Qaddoumi, Ibrahim
    Dhall, Girish
    Pollack, Ian F.
    Lenzen, Alicia
    Partap, Sonia
    Fouladi, Maryam
    Dunkel, Ira
    NEURO-ONCOLOGY, 2020, 22 : 367 - 367
12345